- Home
- ABUS vs RERE Comparison
ABUS vs RERE Comparison
Compare ABUS & RERE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- RERE
- Stock Information
- Founded
- ABUS 2005
- RERE 2011
- Country
- ABUS United States
- RERE China
- Employees
- ABUS N/A
- RERE N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- RERE Other Specialty Stores
- Sector
- ABUS Health Care
- RERE Consumer Discretionary
- Exchange
- ABUS Nasdaq
- RERE Nasdaq
- Market Cap
- ABUS 592.8M
- RERE 678.4M
- IPO Year
- ABUS N/A
- RERE 2021
- Fundamental
- Price
- ABUS $3.24
- RERE $2.28
- Analyst Decision
- ABUS Strong Buy
- RERE
- Analyst Count
- ABUS 4
- RERE 0
- Target Price
- ABUS $5.50
- RERE N/A
- AVG Volume (30 Days)
- ABUS 1.3M
- RERE 1.2M
- Earning Date
- ABUS 05-05-2025
- RERE 05-19-2025
- Dividend Yield
- ABUS N/A
- RERE N/A
- EPS Growth
- ABUS N/A
- RERE N/A
- EPS
- ABUS N/A
- RERE N/A
- Revenue
- ABUS $6,171,000.00
- RERE $2,237,042,920.00
- Revenue This Year
- ABUS $14.57
- RERE $29.57
- Revenue Next Year
- ABUS $15.84
- RERE $24.43
- P/E Ratio
- ABUS N/A
- RERE N/A
- Revenue Growth
- ABUS N/A
- RERE 25.93
- 52 Week Low
- ABUS $2.63
- RERE $1.53
- 52 Week High
- ABUS $4.72
- RERE $3.70
- Technical
- Relative Strength Index (RSI)
- ABUS 50.09
- RERE 38.93
- Support Level
- ABUS $2.71
- RERE $2.00
- Resistance Level
- ABUS $3.32
- RERE $2.25
- Average True Range (ATR)
- ABUS 0.21
- RERE 0.20
- MACD
- ABUS 0.00
- RERE -0.02
- Stochastic Oscillator
- ABUS 63.86
- RERE 26.96
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.